key: cord-0988688-bstw7mrt
authors: Zhang, Ziyun; Penn, Rebecca; Barclay, Wendy S; Giotis, Efstathios S
title: Primary macrophages exhibit a modest inflammatory response early in SARS-CoV-2 infection
date: 2022-02-04
journal: bioRxiv
DOI: 10.1101/2022.02.02.478897
sha: 73d09154a9477209d695d2e57eefd84b54b7b544
doc_id: 988688
cord_uid: bstw7mrt

Involvement of macrophages in the SARS-CoV-2-associated cytokine storm, the excessive secretion of inflammatory/anti-viral factors leading to the acute respiratory distress syndrome (ARDS) in COVID-19 patients, is unclear. In this study, we sought to characterize the interplay between the virus and primary human monocyte-derived macrophages (MDM). MDM were stimulated with recombinant IFN-α and/or infected with either live or UV-inactivated SARS-CoV-2 or with two reassortant influenza viruses containing external genes from the H1N1 PR8 strain and heterologous internal genes from a highly pathogenic avian H5N1 or a low pathogenic human seasonal H1N1 strain. Virus replication was monitored by qRT-PCR for the E viral gene for SARS-CoV-2 or M gene for influenza and TCID50 or plaque assay, and cytokine levels were assessed semiquantitatively with qRT-PCR and a proteome cytokine array. We report that MDM are not susceptible to SARS-CoV-2 whereas both influenza viruses replicated in MDM, albeit abortively. We observed a modest cytokine response in SARS-CoV-2 infected MDM with notable absence of IFN-β induction, which was instead strongly induced by the influenza viruses. Pre-treatment of MDM with IFN-α enhanced proinflammatory cytokine expression upon infection. Together, the findings concur that the hyperinflammation observed in SARS-CoV-2 infection is not driven by macrophages.

The ongoing COVID-19 pandemic has generated many urgent questions on the diverse clinical 36 manifestations of the causative agent Severe Acute Respiratory Syndrome Coronavirus 2 37

(SARS-CoV-2). SARS-CoV-2 requires the binding of its spike surface protein to a cellular 38 receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry into host cells and 39

activation by a host cell proteases TMPRSS2 [1] [2] [3] . The variable expression of ACE2 in different 40

tissues across individuals and polymorphisms in both ACE2 and TMPRSS2 genes contribute to 41 COVID-19 severity/fatality variations [4] [5] [6] [7] . However, the severity of the disease outcome is 42 widely believed to be associated with a derangement of the immune system such as a delayed 43 type I/III interferon response and underlying co-morbidities in infected patients [8, 9] . One of 44 the perplexing hallmarks of SARS-CoV-2 infection is the exacerbated inflammatory response in 45

severe COVID-19 patients resulting in excessive release of pro-inflammatory cytokines known 46

as "cytokine storm", leading in turn to detrimental alveolar damage and fibrosis, progressive 47 respiratory failure and multiple organ dysfunction [10] . A similar excessive inflammatory 48 reaction has been observed in other zoonotic respiratory viruses such as SARS and MERS 49 coronaviruses as well as human infections with avian influenza viruses such as H5N1 [11-13] 50 whereas seasonal influenza induces a less severe response [14] . The prototypical influenza 51

virus-induced cytokine storm has been described to originate from several cell types such as 52 tissue macrophages, mast, endothelial, and epithelial cells [15] . These cells upon virus 53 stimulation release initially TNF-α and IL-1ß, which in-turn stimulate the release of other 54 cytokines mainly IL-1, IL-6, IL-8 and macrophage inflammatory protein-1α (MIP-1α) [13, 15, 55 16]. Although both influenza and COVID-19 are associated with hyperinflammation, there are 56 marked differences between the two conditions in respect of origin, biochemical abnormalities 57

and pathophysiology [17] . Nonetheless, numerous studies have positively correlated the 58 elevated plasma levels of key proinflammatory cytokines in patients with disease severity and 59 mortality for both COVID-19 and highly pathogenic influenza [13-15, 18, 19] . 60

Understanding the precise drivers of SARS-CoV-2-induced hyperinflammation and their 61 correlation to disease outcome is crucial to guide targeted therapeutic interventions. The 62

degree to which SARS-CoV-2 targets the diverse cytokine-producing cells ( Here, we report that primary macrophages are refractory to SARS-CoV-2 and induce modest 82 levels of pro-inflammatory cytokines upon SARS-CoV-2 infection compared to two influenza 83 strains. Pre-exposure of macrophages to exogenous IFN-α exacerbated the virus-induced 84 inflammatory response. These results concur with the findings of previous reports that 85 macrophages are not the original source of pro-inflammatory cytokines early during infection.

Materials and methods 88

Human macrophages were purchased from Lonza Group AG (Switzerland) and were generated 90

in the presence of human macrophage colony-stimulating factor (hM-CSF) from CD14 + human 91 monocytes. Monocytes derived from a 54-year-old, HBV-, HCV-and HIV-negative, African 92

American male. The macrophages were seeded 5×10 5 (0.5 ml) per well, in 24-well plates, with 93 X-Vivo 15 media (Lonza Group AG), 25 ng/l of hM-CSF (Gibco, USA) and 10% Fetal Bovine 94

Serum (Gibco, UK). African green monkey kidney cells (Vero E6; ATCC CRL-1586) were 95 maintained in DMEM, 10% FCS, 1% non-essential amino acids (NEAA) and 1% penicillin-96 streptomycin (P/S). Human epithelial colorectal adenocarcinoma cells (Caco-2; ATCC HTB-37) 97

and human lung cancer cells (Calu-3; ATCC HTB-55) were maintained in DMEM, 20% FCS, 1% 98

NEAA and 1% P/S. All cell cultures in this study were maintained at 37 0 C and 5% CO2. 99

The viral strain used in this study was the lineage B.1 SARS-CoV-2/England/IC19/2020 (IC19) 100

isolate (EPI_ISL_475572) [33] . All work involving the use of SARS-CoV-2 was performed in a 101

Biosafety Level The viruses were diluted in serum-free DMEM (supplemented with 1% NEAA and P/S) to a 117 multiplicity of infection of 0.01 or 1. The inoculum was added to macrophages, Calu-3, Caco-2 118

or Vero E3 cells and incubated at 37 °C for 1h. The inoculum was then removed and cells 119 maintained as described above. 6, 24 or 72h post infection (hpi), the culture supernatants were 120 collected and quantified by TCID50 assay on Vero E6 cells by the Spearman-Karber method [35] 121 or qPCR for the SARS-CoV-2 Envelope gene (E). For the IFN-α experiment, macrophages were 122

pre-treated with 1000 U/ml IFN-α (Invivogen, UK) for 24h before SARS-CoV-2 infection. For 123 treatment with lipopolysaccharide (LPS), cells were treated with 10 μg/ml LPS (Invivogen) for 124

6h. 125 126

For SARS-CoV-2 Envelope (E) and influenza Matrix (M) gene qPCR, RNA was extracted from 128 virus supernatants using the QIAmp Viral RNA kit (Qiagen, UK) as described by the 129 manufacturer (Qiagen, UK). qPCR was performed using the AgPath RT-PCR (Life Technologies, 130 UK) kit on a QuantStudio TM 7 Flex Real-Time PCR system (Applied Biosystems) with the 131

following primers for the E gene: forward: 5'-ACAGGTACGTTAATAGTTAATAGCGT-3', 132

reverse:5'-ATATTGCAGCAGTACGCACACA-3',probe:FAM-ACACTAGCCATCCTTACTGCGCTTCG-133

BBQ. For M vRNA and mRNA analysis, primers and procedures were described previously [34] . 134 A standard curve was also generated using viral RNA dilutions of known copy number to allow 135 absolute quantification of E and M gene copies from Ct values. 136

Cell RNA isolation and RT-qPCR was performed using procedures described previously [36] 137

using the 7900HT Fast Real-Time PCR System (Applied Biosystems). Primers for GAPDH, TNF-138 α, IP-10, IL-6, IL-8, HLA-DR, IFN-α, IFN-β, and ACE2 have been described elsewhere [37] [38] [39] . 139

The output Ct values and dissociation curves were analysed using SDS v2.3 and RQ Manager 140 v1.2 (Applied Biosystems). Gene expression data were normalized against the housekeeping 141

gene GAPDH and compared with the mock controls using the comparative CT method (also 142 referred to as the 2 −ΔΔCT method [40] . All samples were loaded in triplicate.

Chemokine and cytokine detection 145

To assess the expression of cytokines in SARS-CoV-2-infected, uninfected and LPS-stimulated 146 macrophages, we used a Proteome Profiler™ Human XL Cytokine Array Kit (R&D Systems, 147

Minneapolis, MN, USA) which contained 102 different capture antibodies that were spotted on 148 a nitrocellulose membrane, according to the manufacturer's protocol. Immunospots were 149

imaged with the Azure c600 Gel Imaging System (Azure Biosystems, USA) and data ( Figure S1 ) 150

were analysed as spot intensities using Image J (Laboratory for Optical and Computational 151

Instrumentation, USA). For each protein, the average signal of duplicate spots was calculated, 152

corrected for background signals, and normalized to the average signal of the membrane 153 reference spots (relative pixel intensity).

Statistical analyses 156

To determine the significance of differences between experimental groups, one-way ANOVA 157

analysis followed by Tukey's multiple comparisons test were carried out. P-values were set at We initially investigated the ability of human macrophages to support SARS-CoV-2 replication. 172

We infected monolayers of primary human monocyte-derived macrophages ( We assessed productive replication of SARS-CoV-2 by titrating infectious virus in the cell 180 supernatant at 24 and 72h post-infection (hpi) with a standard TCID50 assay on Vero E6 cells, 181

and compared virus yields with those from Calu-3, Vero E6 and Caco-2. We also extracted RNA 182 from the supernatants and the infected cells at 6 hpi and conducted qRT-PCR for the viral 183

transcripts (E for SARS-CoV-2 and M for influenza viruses). We observed no cytopathic effect, 184

no infectious yield and no E gene RT-PCR signal in the cell lysate or the cell-free supernatant of 185 macrophages (Fig. 1A) during infection with SARS-CoV-2. In contrast Caco-2, Vero E6 and Calu-186 3 cell lines produced high viral loads (4 x 10 5 -5.5 x 10 5 TCID50/ml) (Fig. 1A ). Together these 187 findings indicate that macrophages don't support SARS-CoV-2 replication in line with other 188

reports [28] [29] [30] [31] . In contrast, influenza M gene was detected in cell lysates at 6 hpi, more so in 189 6:2 Eng/09 infected macrophages ( Figure S2 ). However, no significant increase of the M gene 190

was detected in the cell culture supernatant infected by either influenza virus at 24 or 72 hpi 191 and no infectious virus was measured by a plaque assay. Thus, the replication of these viruses 192

in MDM is abortive, consistent to a report that only a small subset of influenza strains can 193 productively replicate in primary human macrophages [45] . influenza, we then examined the extent to which exposure of MDM to SARS-CoV-2 and influenza 218

viruses can lead to activation and production of pro-inflammatory cytokines early in infection 219

(6 hpi). We assessed the mRNA induction of innate antiviral and proinflammatory cytokines 220 TNF-α, IP-10, IFN-α, IFN-β, IL-6, IL-8 and the macrophage activation marker HLA-DR in infected 221

or lipopolysaccharide (LPS)-activated MDM. Cell response following exposure to UV-222 inactivated, replication-deficient SARS-CoV-2 virus was also assessed. Results are shown as 223 expression fold change against mock MDM (Fig 1B-F) . The results demonstrate that SARS-CoV-224 2 exposure induced significantly lower expression of IP-10, TNF-α, IL-6 mRNA compared to 225 infection by influenza viruses or stimulation with LPS at 6 hpi. Numerically higher but still 226 modest levels of these cytokines were detected in SARS-CoV-2 infected MDM at 24 hpi. The UV-227 inactivated virus retained the ability to induce IL-6 and IL-8 production (180-and 95-fold 228 respectively). The 6:2 Eng/09 strain induced significantly more (2.5-fold) the expression of 229 TNF-α compared to 6:2 Tky/05. Expression of IFN-α was below detectable levels in all 230 conditions tested. 231

Next, we determined semiquantitatively the cytokine protein levels in the supernatants of mock 232 (6 hpi), SARS-CoV-2-infected (6 and 24 hpi) and LPS-stimulated (hpi) MDM with a Proteome 233

Profiler Human XL Cytokine Array. The array contains four membranes, each spotted in 234 duplicate with 102 different cytokine antibodies. A densitometric evaluation revealed that the 235 proinflammatory cytokines TNF-α, IP-10, IFN-γ, IL-6 and IL-8 cytokines were minimally 236 detected in SARS-CoV-2-exposed MDM compared to mock MDM in line with the qRT-PCR 237 results ( Fig 1G) . Instead, we noticed a significant induction of the Macrophage Inflammatory 238

Protein (MIP-) 1α and 1β. MIP-1α/-1β are monocyte cytokines with inflammatory and 239 chemotactic properties, which interact with CCR1, CCR4, and CCR5 [46] and have been found 240

to be elevated in blood levels of COVID-19 patients (notably those admitted to intensive care 241 units) [47] . Interestingly, the expression of three other cytokines were significantly reduced by 242 SARS-CoV-2 ( Fig 1G) : monocyte chemoattractant protein 1 (MCP1), osteopontin (OPN), and 243 chitinase 3-like 1 (CHI3L1). MCP-1 is a chemokine that attracts monocytes and basophils, but 244 not neutrophils or eosinophils [48] . OPN is an integrin-binding glyco-phosphoprotein involved 245

in the modulation of leukocyte activation [49] and CHI3L1 is a critical regulator of inflammation 246

and innate immunity and a stimulator of ACE2 [50] . The levels of these cytokines are elevated 247

in blood levels of COVID-19 patients and are associated with increased severity of disease. Our 248 findings suggest that secretion of these cytokines are not associated with macrophages at least 249 early in infection.

Priming macrophages with IFNα boosts transcription of proinflammatory cytokines but 252

does not allow productive replication 253

During virus infections, the majority of immune and epithelial cells produce type I interferons 254

(IFNs: IFN-α, -β and -ω) upon sensing a virus. The IFNs do not directly kill the virus. They 255 orchestrate a coordinated antiviral program via the Janus kinase (JAK)-signal transducers, the 256 activators of the transcription (STAT) signaling pathway and the expression of interferon 257 stimulated genes (ISGs), whose protein products directly inhibit virus infection [51] . SARS-258

CoV-2 has been reported to antagonise type I IFN responses in primary cells [52] and severe 259 COVID-19 patients display impaired IFN-α production [53]. We explored whether pre-260 treatment of MDM with IFN-α can trigger an inflammatory response. MDM were pre-treated 261 overnight with exogenous recombinant IFN-α and infected with SARS-CoV-2 for 24h as 262

previously. Results show significantly higher expression levels of TNF-α, IL-6, IL-8 and HLA-DR 263

in IFN-α treated cells compared to the untreated ones (Fig 2A-D) while levels of IFN-β (Fig 2E)  264 and IP-10 (not presented) were below the detection limit. We caveat that the cells we worked with here may reflect a more dominant M2 macrophage 280

population and the observed phenotypes may differ in tissue-resident macrophages. 281

Nevertheless, our findings are aligned with reports that macrophages are unlikely to drive the 282 initial wave of pro-inflammatory cytokines upon SARS-CoV-2 infection [29, 31] . In addition, the 283 substantial increase in induction of proinflammatory cytokines upon IFN-stimulation suggests 284 that macrophages may participate in secondary or ensuing waves of inflammatory responses 285 leading to ARDS in severe COVID-19 patients. 286

Interestingly, we found a significant increase of the subgenomic E gene in the cell lysate of IFN-287 treated MDM but infection was still abortive as we found no new infectious particles in the 288 supernatant (by TCID50 assay and qPCR for the E gene; Fig 2G) . Like others [56], we found that 289

pre-treatment of MDM with IFN-α resulted in induction of ACE2 mRNA (Fig 2F) . ACE2 is the 290 receptor that SARS-CoV-2 uses to infect epithelial cells of lung alveoli and also an ISG [57] . 291

However, a previous report that the ACE2 isoform upregulated by interferon is non-functional 292

for SARS-CoV-2 entry [57], so our results might be explained by other changes to the cells that 293 render them more infectable by the virus. 294

Conflicting reports surround the role of macrophages in SARS-CoV-2 immunopathogenesis and 296

in particular in triggering the cytokine storm that mediates the severity of ARDS in COVID-19 297

patients' lungs. This study provides further evidence that macrophages are refractory to SARS-298

CoV-2. We report that SARS-CoV-2 failed to trigger excessive production of cytokines in 299 macrophages at transcription and protein level, compared to two influenza viruses. We found 300 no evidence for pro-inflammatory cytokine responses upon SARS-CoV-2 exposure. We argue 301 that limited viral internalization or a low replication of SARS-CoV-2 in macrophages may 302 explain the low levels of cytokines induced upon infection compared with influenza viruses. 303

Mirroring other reports, we demonstrate that pre-treatment of macrophages with IFN-α 304

promoted the induction of several pro-inflammatory cytokines but did not render them 305 vulnerable to the virus despite the increased transcription of ACE2. In conclusion, macrophages 306 are unlikely to drive the early wave of pro-inflammatory factors observed in COVID-19 patients 307

with severe disease, but they may exacerbate immune responses later in infection. 308 309 310

Supplementary material 311 Figure S1 : Acknowledgements 320

We thank Jonathan Brown, Jie Zhou, and Thomas Peacock for their technical advice and 321

assistance.

Funding information 324

Research was supported by a Wellcome Trust New Investigator award (104771/Z/14/Z) to 325

Marcus Dorner.

Author Contributions 328 Z.Z. performed experiments, analysed data and wrote first draft of the manuscript; R.P. and 329 E.S.G. performed experiments, analysed data and edited the manuscript; W.S.B. and E.S.G. 330

conceptualized the study, supervised activities and edited the manuscript. All authors have read 331

and agreed to the published version of the manuscript. 332 333

The authors declare no conflict of interest 335

The data used and/or analysed during the current study are available, only for sections non-337

infringing personal information, from the corresponding author on reasonable request. 

CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically 346 proven protease inhibitor

The trinity of COVID-19: 348 immunity, inflammation and intervention

The protein 350 expression profile of ACE2 in human tissues

Individual variation 352 of the SARS-CoV-2 receptor ACE2 gene expression and regulation

Single-cell RNA expression profiling 355 of ACE2, the receptor of SARS-CoV-2

A common TMPRSS2 variant has a protective effect against severe COVID-19

Immune determinants of COVID-19 disease presentation and severity

Untuned antiviral immunity in COVID-19 365 revealed by temporal type I/III interferon patterns and flu comparison

Targeting inflammation and cytokine 368 storm in COVID-19

The Comparative immunological characteristics of SARS-370

Host response to influenza virus: protection versus 372 immunopathology

Influenza infection, SARS, MERS and 374 COVID-19: Cytokine storm -The common denominator and the lessons to be learned

The cytokine storm of severe influenza and development 377 of immunomodulatory therapy

New fronts emerge in the influenza cytokine storm

Cytokines in the systemic inflammatory response 381 syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth

The cytokine storms of COVID-19, H1N1 influenza, 384 CRS and MAS compared. Can one sized treatment fit all? Cytokine

An 390 inflammatory cytokine signature predicts COVID-19 severity and survival

Should we stimulate or suppress immune responses in COVID-19? Cytokine 394 and anti-cytokine interventions

397 Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood 398 mononuclear cells in COVID-19 patients

Cytokine storm in COVID-19: The current 400 evidence and treatment strategies

Macrophages and the recovery from acute and chronic Inflammation

Host-406 Viral infection maps reveal signatures of severe COVID-19 patients

The novel severe acute respiratory syndrome 410 coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes

Contribution of 413 monocytes and macrophages to the local tissue inflammation and cytokine storm in 414 COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions

Comparative tropism, replication kinetics, and cell damage 420 profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, 421 transmissibility, and laboratory studies of COVID-19: an observational study

The lung macrophage in SARS-CoV-2 424 infection: A friend or a foe? Front Immunol

Isolation, sequence, infectivity, and 428 replication kinetics of severe acute respiratory syndrome coronavirus 2

Anzaghe, 431 M., Macrophages and dendritic cells are not the major source of pro-inflammatory 432 cytokines upon SARS-CoV-2 infection

Monocytes and macrophages, 435 targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis

SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial 439 infection to macrophage inflammation

Attenuated 442 interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells 443 is associated with viral antagonism of STAT1 phosphorylation

The antiandrogen enzalutamide downregulates 447 TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells

Internal genes of a highly pathogenic 451 H5N1 influenza virus determine high viral replication in myeloid cells and severe 452 outcome of infection in mice

Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche

Arch. f.ür. experimentellePathologie und Pharmakologie

Constitutively elevated levels of SOCS1 suppress innate responses in DF-1 immortalised 458 chicken fibroblast cells

Delayed induction of proinflammatory cytokines and suppression of 461 innate antiviral response by the novel Middle East respiratory syndrome coronavirus: 462 implications for pathogenesis and treatment

Entry of the bat influenza H17N10 virus into 465 mammalian cells is enabled by the MHC class II HLA-DR receptor

Species difference in ANP32A underlies 469 influenza A virus polymerase host restriction

A new mathematical model for relative quantification in real-time RT-PCR. 471

Elevated plasma levels of selective cytokines in 475 COVID-19 patients reflect viral load and lung injury

The resolution of 478 inflammation

Dendritic cells, monocytes and macrophages: a unified 481 nomenclature based on ontogeny

Major alterations in the mononuclear phagocyte landscape associated with 487 COVID-19 severity

Influenza virus 489 overcomes cellular blocks to productively replicate, impacting macrophage function

CCL3 Signaling in the Tumor 492 Microenvironment

An immune-based biomarker signature is 501 associated with mortality in COVID-19 patients

IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

Circulating 507 osteopontin levels and outcomes in patients hospitalized for COVID-19

Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19

Systematic identification of type I and 514 type II interferon-induced antiviral factors

Imbalanced host response to SARS-CoV-2 drives development of COVID-519 19

Impaired type I interferon activity and inflammatory responses in severe 525 COVID-19 patients

Type I and III interferon responses in SARS-CoV-2 infection

Dysregulated type I interferon and inflammatory monocyte-macrophage responses 530 cause lethal pneumonia in SARS-CoV-infected mice

SARS-CoV-2 Receptor ACE2 is an interferon-stimulated 543 gene in human airway epithelial cells and is detected in specific cell subsets across 544 tissues

Tissue-specific and interferon-inducible expression of nonfunctional ACE2 547 through endogenous retroelement co-option